- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? | 11 | Benzinga.com | ||
| 18.12.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies | 227 | GlobeNewswire (Europe) | - Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy... ► Artikel lesen | |
| 18.12.24 | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 26.11.24 | Cognition Therapeutics schließt Phase-2-Studie zu DLB ab | 6 | Investing.com Deutsch | ||
| 26.11.24 | Cognition Therapeutics concludes Phase 2 DLB study | 1 | Investing.com | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.11.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies | 116 | GlobeNewswire (Europe) | - Topline results in second dementia indication expected to be reported in December 2024 - PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage... ► Artikel lesen | |
| 25.11.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population | 2 | GlobeNewswire (USA) | ||
| 13.11.24 | Cognition Therapeutics GAAP EPS of -$0.25 | 6 | Seeking Alpha | ||
| 13.11.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update | 230 | GlobeNewswire (Europe) | - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to... ► Artikel lesen | |
| 13.11.24 | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.24 | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum | 1 | GlobeNewswire (USA) | ||
| 31.10.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD | 2 | GlobeNewswire (USA) | ||
| 29.10.24 | Cognition Therapeutics berichtet über potenziellen Durchbruch bei Alzheimer-Behandlung | 5 | Investing.com Deutsch | ||
| 29.10.24 | Cognition Therapeutics reports potential Alzheimer's treatment breakthrough | 1 | Investing.com | ||
| 29.10.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD | 143 | GlobeNewswire (Europe) | - Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed... ► Artikel lesen | |
| 23.10.24 | Cognition Therapeutics, Inc.: Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD | 117 | GlobeNewswire (Europe) | Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in 'SHINE' Poster Presentation details baseline characteristics from the signal-finding 'SHIMMER' trial in DLB PURCHASE... ► Artikel lesen | |
| 22.10.24 | Cognition Therapeutics, Inc.: Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) | 4 | GlobeNewswire (USA) | ||
| 08.10.24 | Cognition Therapeutics stock hits 52-week low at $0.4 | 2 | Investing.com |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 112,00 | -0,53 % | Kaufempfehlung bekräftigt: BioNTech: Spannende Pipeline macht Hoffnung auf deutlichen Kursanstieg | © Foto: Julia Cebella - dpaDie Analysten von Berenberg Research sehen großes Potenzial in BioNTechs Onkologie-Pipeline und betonen, dass die bevorstehenden klinischen Auswertungen bis 2025 die Bewertung... ► Artikel lesen | |
| CUREVAC | 3,596 | -2,23 % | CureVac mit EILMELDUNG: Analysten rechnen mit unfassbarem Kursfeuerwerk - Das sind die Hintergründe! | ||
| AMGEN | 262,00 | -0,19 % | Granite Group Advisors LLC Has $2.29 Million Holdings in Amgen Inc. (NASDAQ:AMGN) | ||
| NOVAVAX | 8,564 | -2,47 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BIOGEN | 137,85 | -1,04 % | Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease | Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,110 | -2,37 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| INTELLIA THERAPEUTICS | 9,628 | -7,95 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,190 | -1,51 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,310 | -5,35 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,543 | -3,39 % | What Analysts Are Saying About Pacific Biosciences Stock | ||
| EXELIXIS | 30,980 | +0,42 % | Exelixis Aktie: Fachmeinungen und Analysen | Die Aktie des Onkologieunternehmens Exelixis verzeichnete am 25. Januar 2025 eine moderate Kurssteigerung von 0,29 Prozent auf 30,70 EUR. Diese Entwicklung erfolgt zeitgleich mit einer bedeutsamen Neubewertung... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 111,00 | +0,05 % | Sarepta Reports Positive Phase 3 EMBARK Data For Elevidys In Duchenne Muscular Dystrophy | WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the... ► Artikel lesen | |
| VAXART | 0,700 | -6,73 % | Vaxart, Inc. - 8-K, Current Report | ||
| EXACT SCIENCES | 51,94 | -2,64 % | Exact Sciences taps into TV dramas for 'tongue-in-cheek' Cologuard campaign |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,760 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.
